journal article·2025-03-18Open access

Extracellular Vesicles Carrying Tenascin-C are Clinical Biomarkers and Improve Tumor-Derived DNA Analysis in Glioblastoma Patients

Amanda Salviano-Silva, Kathrin Wollmann, Santra Brenna, Rudolph Reimer, Julia E. Neumann, Matthias Dottermusch, Laura Woythe, Cecile L. Maire, Berta Puig, Ulrich Schüller, Meike J. Saul, Manfred Westphal, Richard Drexler, Lasse Dührsen, Jens Gempt, Dieter H. Heiland, Katrin Lamszus, Franz L. Ricklefs

ACS Nano· Volume 19· Issue 10

Abstract

High Resolution Image Download MS PowerPoint Slide Extracellular vesicles (EVs) act as carriers of biological information from tumors to the bloodstream, enabling the detection of circulating tumor material and tracking of disease progression. This is particularly crucial in glioblastoma, a highly aggressive and heterogeneous tumor that is challenging to monitor. Using imaging flow cytometry (IFCM), we conducted an immunophenotyping analysis of eight glioma-associated antigens and tetraspanins in plasma EVs from 37 newly diagnosed glioblastoma patients (pre- and post-surgery), 11 matched individuals with recurrent glioblastoma, and 22 healthy donors (HD). Tenascin-C (TNC) positive EVs displayed the strongest differences in newly diagnosed and recurrent glioblastoma patients, when compared to non-tumor subjects. Among dual-positive subpopulations, TNC + /CD9 + EVs were the most elevated in newly diagnosed (FC = 7.6, p <0.0001, AUC = 81%) and recurrent patients (FC = 16.5, p <0.0001; AUC = 90%) than HD. In comparison with other CNS tumors ( n = 25), this subpopulation was also 34.5-fold higher in glioblastoma than in meningioma cases ( p <0.01). Additionally, TNC + /CD9 + EV levels were 3.3-fold elevated in cerebrospinal fluid from glioblastoma patients ( n = 6) than controls ( p <0.05). Aberrant TNC levels were further observed in glioblastoma EVs from different sources and purified via different methods. Immunohistochemical analysis revealed high levels of TNC in tumor tissues. Spatial transcriptomic analysis indicated a TNC overexpression in malignant cell populations of glioblastoma resections, particularly in cells with mesenchymal-like signatures and chromosomal aberrations. Lastly, we purified TNC + EVs from plasma of 21 glioblastoma patients by magnetic sorting and detected the oncogenic mutation TERT*C228T by droplet digital PCR. The mutant allele frequency was higher in TNC + EVs vs TNC-negative EVs (FC = 32, p <0.001), total EVs (FC = 5.3, p <0.001) or cell-free DNA (FC = 5.3, p <0.01). In conclusion, circulating TNC + EVs may have potential as clinical biomarkers in glioblastoma, and their purification could improve the identification of tumor-specific mutations in liquid biopsies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · Cell Adhesion Molecules Research · Caveolin-1 and cellular processes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Neurosurgery

University Medical Center Hamburg-Eppendorf

Neurology Department, Experimental Research in Stroke and Inflammation

Leibniz Institute for Experimental Virology

Institute of Neuropathology

Center for Molecular Neurobiology (ZMNH)

Oxford Nanoimaging Limited (ONI)

Department of Pediatric Hematology and Oncology

Children’s Cancer Research Center Hamburg

Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg

University Clinic Hamburg-Eppendorf

Medical Center University of Freiburg

Translational Neurosurgery

Friedrich-Alexander University Erlangen Nuremberg

University Hospital Erlangen, Friedrich-Alexander University Erlangen Nuremberg

Funding

Anni Hofmann Stiftung · Deutsche Forschungsgemeinschaft · Rudolf Bartling Stiftung

References (70)

Show source-provided references
1. 10.1093/neuonc/noab10610.1093/neuonc/noab106 ↗
2. 10.3390/cancers1304076110.3390/cancers13040761 ↗
3. 10.1016/j.ctarc.2021.10049010.1016/j.ctarc.2021.100490 ↗
4. 10.3402/jev.v4.2706610.3402/jev.v4.27066 ↗
5. 10.1093/neuonc/noab22910.1093/neuonc/noab229 ↗
6. 10.1158/1078-0432.CCR-18-194110.1158/1078-0432.CCR-18-1941 ↗
7. 10.1080/20013078.2019.158855510.1080/20013078.2019.1588555 ↗
8. 10.1093/neuonc/noae06810.1093/neuonc/noae068 ↗
9. 10.1093/neuonc/noab01210.1093/neuonc/noab012 ↗
10. 10.1515/labmed-2022-004710.1515/labmed-2022-0047 ↗
11. 10.1038/s41591-024-02969-w10.1038/s41591-024-02969-w ↗
12. 10.18632/oncotarget.1363510.18632/oncotarget.13635 ↗
13. 10.1038/s41598-023-40425-w10.1038/s41598-023-40425-w ↗
14. 10.1007/s11060-015-1864-410.1007/s11060-015-1864-4 ↗
15. 10.14791/btrt.2022.003110.14791/btrt.2022.0031 ↗
16. 10.1371/journal.pone.023461410.1371/journal.pone.0234614 ↗
17. 10.1016/S0167-4889(00)00056-210.1016/S0167-4889(00)00056-2 ↗
18. 10.1111/cas.1371110.1111/cas.13711 ↗
19. 10.1016/j.jneuroim.2015.11.02510.1016/j.jneuroim.2015.11.025 ↗
20. 10.1096/fj.08-12218410.1096/fj.08-122184 ↗
21. 10.1371/journal.pone.004206410.1371/journal.pone.0042064 ↗
22. 10.1080/2162402X.2018.147864710.1080/2162402X.2018.1478647 ↗
23. 10.1007/978-3-030-48457-6_910.1007/978-3-030-48457-6_9 ↗
24. 10.1200/JCO.2005.03.408210.1200/JCO.2005.03.4082 ↗
25. 10.1007/s11060-016-2298-310.1007/s11060-016-2298-3 ↗
26. 10.1002/ijc.3426110.1002/ijc.34261 ↗
27. 10.1038/s42003-019-0560-x10.1038/s42003-019-0560-x ↗
28. 10.1016/j.bios.2021.11347610.1016/j.bios.2021.113476 ↗
29. 10.1038/s41392-021-00499-210.1038/s41392-021-00499-2 ↗
30. 10.1186/s40364-022-00404-110.1186/s40364-022-00404-1 ↗
31. 10.1002/jev2.1211010.1002/jev2.12110 ↗
32. 10.1002/jev2.1240410.1002/jev2.12404 ↗
33. 10.1038/nmeth.418510.1038/nmeth.4185 ↗
34. 10.1093/neuonc/now24710.1093/neuonc/now247 ↗
35. 10.1016/j.eplepsyres.2014.09.01910.1016/j.eplepsyres.2014.09.019 ↗
36. 10.3389/fimmu.2020.60758710.3389/fimmu.2020.607587 ↗
37. 10.1101/2022.08.27.50543910.1101/2022.08.27.505439 ↗
38. 10.1016/j.ccell.2022.05.00910.1016/j.ccell.2022.05.009 ↗
39. 10.1007/s00432-021-03536-310.1007/s00432-021-03536-3 ↗
40. 10.1016/j.tranon.2018.10.00210.1016/j.tranon.2018.10.002 ↗
41. 10.1038/ncb295410.1038/ncb2954 ↗
42. 10.1074/jbc.RA120.01396310.1074/jbc.RA120.013963 ↗
43. 10.1038/s41419-023-05812-110.1038/s41419-023-05812-1 ↗
44. Bourdon M. A. · Cancer Res. · 1983 · 43 · 2796
45. 10.1016/j.ccell.2017.02.00910.1016/j.ccell.2017.02.009 ↗
46. 10.1172/jci.insight.12226410.1172/jci.insight.122264 ↗
47. 10.1016/j.celrep.2023.11219710.1016/j.celrep.2023.112197 ↗
48. 10.1200/JCO.2009.26.354110.1200/JCO.2009.26.3541 ↗
49. 10.3390/cancers1212365210.3390/cancers12123652 ↗
50. 10.3389/fimmu.2021.63610810.3389/fimmu.2021.636108 ↗
51. 10.1111/1759-7714.1462410.1111/1759-7714.14624 ↗
52. 10.1007/BF0228482110.1007/BF02284821 ↗
53. 10.1242/jcs.19054610.1242/jcs.190546 ↗
54. 10.1186/s40478-015-0213-310.1186/s40478-015-0213-3 ↗
55. 10.1002/cncr.1179610.1002/cncr.11796 ↗
56. 10.1186/s12987-022-00359-310.1186/s12987-022-00359-3 ↗
57. 10.1186/s40478-017-0465-110.1186/s40478-017-0465-1 ↗
58. 10.3389/fonc.2022.97146210.3389/fonc.2022.971462 ↗
59. 10.1016/j.celrep.2016.11.01210.1016/j.celrep.2016.11.012 ↗
60. 10.1093/neuonc/nov17110.1093/neuonc/nov171 ↗
61. 10.1007/s12031-021-01832-810.1007/s12031-021-01832-8 ↗
62. 10.3390/cancers1506187910.3390/cancers15061879 ↗
63. 10.1186/s40478-019-0727-110.1186/s40478-019-0727-1 ↗
64. 10.1242/jcs.26024410.1242/jcs.260244 ↗
65. 10.3389/fimmu.2021.67148510.3389/fimmu.2021.671485 ↗
66. 10.1038/s41596-020-00466-110.1038/s41596-020-00466-1 ↗
67. 10.1002/cyto.a.2403410.1002/cyto.a.24034 ↗
68. 10.1038/nmeth.201910.1038/nmeth.2019 ↗
69. 10.1038/s41467-022-28523-110.1038/s41467-022-28523-1 ↗
70. 10.1038/nature2600010.1038/nature26000 ↗